-transparent.png){kind=logo}
OBJECTIVE Retinoids are known to exhibit a broad spectrum of biological activities, and they participate in the onset of differentiation and the inhibition of growth in a wide variety of cancer cells. Some of these vitamin A derivatives are already in clinical use. However, data on retinoid actions in glial tumors are rather sparse. Therefore, we studied the effects of the natural retinoic acid (RA) forms all-trans-RA, 9-cis-RA, and 13-cis-RA on glioma cell lines and primary cultures from patients with glioblastomas multiforme. METHODS Six human glioma cell lines, one rat glioma cell line, and 20 primary cultures established from biopsies from patients with glioblastomas multiforme were investigated. Tumor cell proliferation was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and cell-counting assays. Random migration out of tumor spheroids was quantified using a video-morphometry system. Invasion was investigated using a confrontational coculture test system. Retinoid receptor (RA receptor [RAR]alpha, -beta, and -gamma and retinoid X receptor [RXR]alpha, -beta, and -gamma) expression status was determined using reverse transcription-polymerase chain reaction studies. RESULTS Treatment of five human glioma cell lines with the different retinoids at concentrations up to 10(-5) mol/L produced no reduction of proliferation, using various incubation times. For one human glioma cell line (U343MG-A) and one rat glioma cell line (C6), which were previously reported to be sensitive to retinoids, we could confirm strong inhibitory effects on proliferation and clear changes in morphological features after retinoid treatment. Application of the different retinoids to low-passage primary cultures of human glioblastomas resulted in marked inhibition of proliferation (30-95%) for all tested samples. Using three-dimensional spheroid cultures, we detected retinoid-induced decreases in cell migration (24-65%). Invasion was not affected by these vitamin A derivatives. In an analysis of the expression patterns for retinoid receptors (RARs and RXRs), all primary culture samples yielded positive results for RAR gamma and RXR alpha and negative results for RAR alpha, RAR beta, and RXR gamma, whereas the results of RXR beta expression were heterogeneous among different patients. The cell lines, irrespective of their RA sensitivities, did not exhibit any major differences in receptor expression. CONCLUSIONS Retinoids strongly inhibit proliferation and migration in primary cultures of human glioblastomas multiforme. Our data support a clinical trial of retinoids for the treatment of human malignant gliomas. We observed that most established cell lines were not sensitive to RA. This difference between long-term cell lines and primary cultures cannot be explained by different retinoid receptor expression patterns.
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
January 1995,
European journal of cancer (Oxford, England : 1990),
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
November 1986,
Biochemical and biophysical research communications,
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
August 1990,
Journal of neurocytology,
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
January 1985,
Anticancer research,
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
October 2014,
Journal of medicinal chemistry,
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
December 1961,
Experimental cell research,
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
January 1990,
Anticancer research,
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
January 1978,
Progress in clinical and biological research,
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
January 1999,
Toxicology in vitro : an international journal published in association with BIBRA,
H Bouterfa, and
T Picht, and
D Kess, and
C Herbold, and
E Noll, and
P M Black, and
K Roosen, and
J C Tonn
September 1996,
Brain research. Molecular brain research,
